Powered by

-BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results

Nov 20, 2018 - ENP Newswire

Jerusalem - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today issued a clarification regarding information published on November 13, 2018 in connection with the third quarter financial results.

As correctly indicated in the financial tables filed on November 14, 2018 in a 6-K with the United States Securities And Exchange Commission (SEC), third quarter o...